Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
Liquidia (NASDAQ: LQDA) announced the presentation of nine encore thematic posters at the PHA 2024 International PH Conference and Scientific Sessions in Indianapolis, Indiana. The posters, to be presented on August 16-17, 2024, focus on the company's investigational products: YUTREPIA™ (treprostinil inhalation powder) and L606 (liposomal treprostinil inhalation suspension sustained-release formulation). These products are being developed for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The posters cover various aspects of clinical trials, including safety, efficacy, pharmacokinetics, and quality of life assessments for both YUTREPIA™ and L606. Key studies presented include the INSPIRE study for YUTREPIA™ and a Phase 3 study for L606. The presentations also explore innovative approaches such as cardiac effort measurement and high-resolution computed tomography for drug deposition analysis.
Liquidia (NASDAQ: LQDA) ha annunciato la presentazione di nove poster tematici durante il PHA 2024 International PH Conference and Scientific Sessions a Indianapolis, Indiana. I poster, che saranno presentati il 16-17 agosto 2024, si concentrano sui prodotti in fase di sviluppo dell'azienda: YUTREPIA™ (polvere per inalazione di treprostinil) e L606 (sospensione per inalazione liposomiale di treprostinil a rilascio prolungato). Questi prodotti sono in fase di sviluppo per il potenziale trattamento della ipertensione arteriosa polmonare (PAH) e dell'ipertensione polmonare associata a malattie interstiziali del polmone (PH-ILD).
I poster coprono vari aspetti delle sperimentazioni cliniche, inclusi sicurezza, efficacia, farmacocinetica e valutazioni della qualità della vita per YUTREPIA™ e L606. Gli studi chiave presentati includono lo studio INSPIRE per YUTREPIA™ e uno studio di Fase 3 per L606. Le presentazioni esplorano anche approcci innovativi come la misurazione dello sforzo cardiaco e la tomografia computerizzata ad alta risoluzione per l'analisi del deposito del farmaco.
Liquidia (NASDAQ: LQDA) anunció la presentación de nueve carteles temáticos en la PHA 2024 International PH Conference and Scientific Sessions en Indianápolis, Indiana. Los carteles, que se presentarán el 16 y 17 de agosto de 2024, se centran en los productos en investigación de la compañía: YUTREPIA™ (polvo para inhalación de treprostinilo) y L606 (suspensión liposomal de treprostinilo para inhalación de formulación de liberación sostenida). Estos productos se están desarrollando para el tratamiento potencial de la hipertensión arterial pulmonar (PAH) y la hipertensión pulmonar asociada con enfermedades intersticiales del pulmón (PH-ILD).
Los carteles cubren varios aspectos de los ensayos clínicos, incluyendo seguridad, eficacia, farmacocinética y evaluaciones de calidad de vida para YUTREPIA™ y L606. Los estudios clave presentados incluyen el estudio INSPIRE para YUTREPIA™ y un estudio de Fase 3 para L606. Las presentaciones también exploran enfoques innovadores como la medición del esfuerzo cardíaco y la tomografía computarizada de alta resolución para el análisis de depósitos de medicamentos.
리퀴디아 (NASDAQ: LQDA)는 인디애나주 인디애나폴리스에서 열리는 PHA 2024 국제 폐고혈압 회의 및 과학 세션에서 9개의 주제 포스터를 발표할 예정이라고 발표했습니다. 2024년 8월 16일부터 17일에 발표될 포스터는 회사의 조사 제품인 YUTREPIA™ (트레포스틴일 흡입 분말)과 L606 (지속 방출 형식의 리포좀 트레포스틴일 흡입 현탁액)에 초점을 맞추고 있습니다. 이들 제품은 폐동맥 고혈압 (PAH) 및 간질폐질환 관련 폐고혈압 (PH-ILD)의 잠재적 치료를 위해 개발되고 있습니다.
포스터는 YUTREPIA™와 L606에 대한 안전성, 유효성, 약물 동태학 및 삶의 질 평가를 포함한 임상 시험의 다양한 측면을 다룹니다. 소개된 주요 연구로는 YUTREPIA™에 대한 INSPIRE 연구와 L606의 3상 연구가 있습니다. 발표에서도 심장 노력 측정 및 약물 침착 분석을 위한 고해상도 컴퓨터 단층촬영과 같은 혁신적인 접근법이 탐구됩니다.
Liquidia (NASDAQ: LQDA) a annoncé la présentation de neuf posters thématiques lors de la PHA 2024 International PH Conference and Scientific Sessions à Indianapolis, Indiana. Les posters, qui seront présentés les 16 et 17 août 2024, sont axés sur les produits investigués de la société : YUTREPIA™ (poudre d'inhalation de tréprostinil) et L606 (suspension d'inhalation liposomale de tréprostinil à libération prolongée). Ces produits sont développés pour le traitement potentiel de l'hypertension artérielle pulmonaire (PAH) et de l'hypertension pulmonaire associée à une maladie pulmonaire interstitielle (PH-ILD).
Les posters couvrent divers aspects des essais cliniques, y compris la sécurité, l'efficacité, la pharmacocinétique et les évaluations de la qualité de vie pour YUTREPIA™ et L606. Les études clés présentées incluent l'étude INSPIRE pour YUTREPIA™ et une étude de phase 3 pour L606. Les présentations explorent également des approches innovantes telles que la mesure de l'effort cardiaque et la tomodensitométrie à haute résolution pour l'analyse du dépôt du médicament.
Liquidia (NASDAQ: LQDA) hat die Präsentation von neun thematischen Postern auf der PHA 2024 International PH Conference and Scientific Sessions in Indianapolis, Indiana, angekündigt. Die Poster, die am 16. und 17. August 2024 präsentiert werden sollen, konzentrieren sich auf die Untersuchungsprodukte des Unternehmens: YUTREPIA™ (Treprostinil-Inhalationspulver) und L606 (Liposomale Treprostinil-Inhalationssuspension mit nachhaltiger Freisetzung). Diese Produkte werden entwickelt, um potenziell die pulmonale arterielle Hypertension (PAH) und die mit interstitieller Lungenerkrankung assoziierte pulmonale Hypertension (PH-ILD) zu behandeln.
Die Poster decken verschiedene Aspekte klinischer Prüfungen ab, einschließlich Sicherheit, Wirksamkeit, Pharmakokinetik und Lebensqualitätsbewertungen für sowohl YUTREPIA™ als auch L606. Zu den vorgestellten Schlüsselergebnissen gehören die INSPIRE-Studie für YUTREPIA™ und eine Phase-3-Studie für L606. Die Präsentationen erkunden auch innovative Ansätze wie die Messung von Herzbelastungen und die hochauflösende Computertomographie zur Analyse der Arzneimittelablagerung.
- Presentation of nine posters at a major international conference, demonstrating ongoing research and development efforts
- Focus on two investigational products for treating PAH and PH-ILD, potentially expanding the company's market reach
- Diverse range of studies covering safety, efficacy, pharmacokinetics, and quality of life assessments, providing comprehensive data on the products
- None.
MORRISVILLE, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), announced today the company will present nine encore thematic posters at the PHA 2024 International PH Conference and Scientific Sessions taking place August 15 to August 18, 2024 in Indianapolis, Indiana.
The company’s posters, which will be presented on Friday, August 16, 2024 from 8:00 a.m. – 5:30 p.m. EDT and Saturday, August 17, 2024 from 9:00 a.m. – 1:00 p.m. EDT, focus on the company’s investigational products, YUTREPIA™ (treprostinil) inhalation powder, and L606 (liposomal treprostinil) inhalation suspension sustained-release formulation, both for the potential treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Encore Thematic Poster Sessions
Poster 1003 - A Phase 3, 2-Part, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects with PAH and PH-ILD. Presented by Savan Patel, Liquidia Technologies.
Poster 1011 - Cardiac Effort in Pulmonary Hypertension – Interstitial Lung Disease: A New and Personalized Clinical Trial Outcome. Cardiac Effort in Pulmonary Hypertension – Interstitial Lung Disease: A New and Personalized Clinical Trial Outcome. Presented by Savan Patel, Liquidia Technologies.
Poster 1013 - Clinical Pharmacokinetics of an Extended-Release Formulation of Inhaled Liposomal Treprostinil (L606) to Reduce Dosing Frequency. Presented by Savan Patel, Liquidia Technologies.
Poster 1025 - Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (YUTREPIA™). Presented by Savan Patel, Liquidia Technologies.
Poster 1030 - High Resolution Computed Tomography (HRCT) Chest Scans to examine the association between regional drug deposition of LIQ861 (YUTREPIA™) and vasodilation in PH-ILD population. Presented by Savan Patel, Liquidia Technologies.
Poster 1054 - Quality of Life (QOL) in PAH patients receiving an inhaled dry powder treprostinil (LIQ861) in the INSPIRE study. Presented by Savan Patel, Liquidia Technologies.
Poster 1058 - Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights from the INSPIRE Study with LIQ861 (YUTREPIA™). Presented by Savan Patel, Liquidia Technologies.
Poster 1059 - Safety and Tolerability of LIQ861 (YUTREPIA™) In Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study. Presented by Savan Patel, Liquidia Technologies.
Poster 1063 - The ASCENT Study: An Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension. Presented by Savan Patel, Liquidia Technologies.
All posters are available on Liquidia’s website at https://liquidia.com/products-and-pipeline/publications.
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. The FDA previously issued tentative approval of YUTREPIA for the PAH indication in November 2021. In July 2023, Liquidia filed an amendment to its New Drug Application for YUTREPIA, seeking to add PH-ILD to the label. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, with the objective of informing YUTREPIA’s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About L606 (liposomal treprostinil) inhalation suspension
L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period and potentially mitigating local and systemic side effects. L606 is currently being evaluated in an open-label study in the United States for the treatment of PAH and PH-ILD with a planned global, pivotal, placebo-controlled efficacy study for the treatment of PH-ILD.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Remodulin® and Tyvaso® are registered trademarks of United Therapeutics Corporation.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
What products is Liquidia (LQDA) presenting at the PHA 2024 Conference?
When and where is Liquidia (LQDA) presenting its posters at the PHA 2024 Conference?
What are the key studies Liquidia (LQDA) is presenting at the PHA 2024 Conference?
How many posters is Liquidia (LQDA) presenting at the PHA 2024 Conference?
